Published by Josh White on 3rd January 2023
(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for 'ESLIM-01', a pivotal phase 3 clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (ITP) in China.
URL: http://www.digitallook.com/dl/news/story/33210983/...